


Supplement Table. Adverse event summary

n (%)	Patients with RRMS	HCs
	n = 23	n = 15
≥ 1 AE	22 (96)	8 (53)
≥ 1 treatment-related AE ^a	16 (70)	0
≥ 1 severe AE ^b	4 (17)	0
≥ 1 serious AE	1 (4)	0
≥ 1 AE resulting in discontinuation of study drug	1 (4) ^c	0
Most common (≥3) TEAEs, n (%) ^d	Patients with RRMS n = 23	
Influenza-like illness	9 (39)	
Injection-site reaction	8 (35)	
Multiple sclerosis relapse	5 (22)	
Fatigue	4 (17)	
Injection-site pain	4 (17)	
Nasopharyngitis	4 (17)	
Headache	3 (13)	
Migraine	3 (13)	
Muscular weakness	3 (13)	
Nausea	3 (13)	

AE; adverse event; HC, healthy control; RRMS, relapsing-remitting multiple sclerosis; TEAE, treatment-emergent AE
^aRelationship = possible, probable, missing. ^bIncludes missing severity. ^cAction taken = medication permanently stopped.
^dNo TEAE was seen in ≥3 subjects in the HC group.



Supplement Figure 1